- Home
- SHW vs GSK Comparison
SHW vs GSK Comparison
Compare SHW & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHW
- GSK
- Stock Information
- Founded
- SHW 1866
- GSK 1715
- Country
- SHW United States
- GSK United Kingdom
- Employees
- SHW N/A
- GSK N/A
- Industry
- SHW RETAIL: Building Materials
- GSK Biotechnology: Pharmaceutical Preparations
- Sector
- SHW Consumer Discretionary
- GSK Health Care
- Exchange
- SHW Nasdaq
- GSK Nasdaq
- Market Cap
- SHW 88.6B
- GSK 77.4B
- IPO Year
- SHW N/A
- GSK N/A
- Fundamental
- Price
- SHW $340.06
- GSK $37.77
- Analyst Decision
- SHW Buy
- GSK Hold
- Analyst Count
- SHW 17
- GSK 2
- Target Price
- SHW $382.50
- GSK N/A
- AVG Volume (30 Days)
- SHW 1.7M
- GSK 6.1M
- Earning Date
- SHW 07-22-2025
- GSK 07-30-2025
- Dividend Yield
- SHW 0.93%
- GSK 4.14%
- EPS Growth
- SHW 2.71
- GSK N/A
- EPS
- SHW 10.08
- GSK 0.98
- Revenue
- SHW $23,079,900,000.00
- GSK $40,735,668,430.00
- Revenue This Year
- SHW $2.47
- GSK $6.70
- Revenue Next Year
- SHW $4.74
- GSK $5.42
- P/E Ratio
- SHW $33.76
- GSK $18.45
- Revenue Growth
- SHW 0.31
- GSK 2.57
- 52 Week Low
- SHW $308.84
- GSK $31.72
- 52 Week High
- SHW $400.42
- GSK $44.67
- Technical
- Relative Strength Index (RSI)
- SHW 43.35
- GSK 45.98
- Support Level
- SHW $338.80
- GSK $35.45
- Resistance Level
- SHW $347.10
- GSK $38.90
- Average True Range (ATR)
- SHW 5.69
- GSK 0.87
- MACD
- SHW -0.33
- GSK 0.01
- Stochastic Oscillator
- SHW 40.89
- GSK 46.03
About SHW Sherwin-Williams Company (The)
Sherwin-Williams is the largest provider of architectural paint in the United States. The company has over 5,000 stores and sells premium paint at higher price points than most competitors. Sherwin-Williams also sells paint-related products in big-box stores and provides coatings for original equipment manufacturers.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.